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Abstract: In the studies of genomics, it is essential to select a small number of genes that are 
more signiﬁ  cant than the others for research ranging from candidate gene studies to genome-wide 
association studies. In this study, we proposed a Bayesian method for identifying the promis-
ing candidate genes that are signiﬁ  cantly more inﬂ  uential than the others. We employed the 
framework of variable selection and a Gibbs sampling based technique to identify signiﬁ  cant 
genes. The proposed approach was applied to a genomics study for persons with chronic fatigue 
syndrome. Our studies show that the proposed Bayesian methodology is effective for deriving 
models for genomic studies and for providing information on signiﬁ  cant genes.
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Introduction
In the studies of genomics, the problem of identifying signiﬁ  cant genes remains a 
challenge for researchers. Single nucleotide polymorphisms (SNPs) can be used in 
clinical association studies to determine the contribution of genes to disease suscepti-
bility or drug efﬁ  cacy. By using candidate gene approaches or genome-wide associa-
tion studies, the key goal is to ﬁ  nd responsible genes and SNPs for certain events (for 
example, certain diseases or certain drug efﬁ  cacy). It is vital to select a small number 
of SNPs that are more signiﬁ  cant than the others and ignoring the SNPs of lesser 
signiﬁ  cance, thereby allowing researchers to focus on the most promising candidate 
genes and SNPs for diagnostics and therapeutics (Lee et al 2003; Lin et al 2007a). As 
we have 2p models with p SNPs, exhaustive computation over this model space is not 
feasible when the model space is very large (Lee et al 2003).
A variety of Bayesian variable selection methods based on Markov chain Monte 
Carlo (MCMC) approaches have been proposed for variable selection including 
the stochastic search variable selection (SSVS) of George and McCulloch (1993), 
the unconditional priors (UP) approach of Kuo and Mallick (1998), and the Gibbs 
variable selection (GVS) by Dellaportas and colleagues (2000, 2002). These three 
Bayesian variable selection methods utilize one particular MCMC method, the 
Gibbs sampler. The SSVS method has been applied to the identiﬁ  cation of quantita-
tive trait loci (QTL) and treats mapping QTL as a problem of model determination 
and variable selection (Yi et al 2003). Lee and colleagues (2003) applied the SSVS 
method to the problem of gene selection with microarray data for discovering sig-
niﬁ  cant disease genes on breast tumors. Similarly, Oh and colleagues (2003) utilized 
the SSVS method to identify the markers that are associated with the disease genes 
related to a high rate of increase in cholesterol. Furthermore, the SSVS approach was 
extended to the multivariate regression model in the multivariate Bayesian variable 
selection method (Brown et al 1998). Sha and colleagues (2004) used the multivari-
ate Bayesian variable selection method to classify disease stages in microarray data. 
In addition, Swartz and colleagues (2006, 2007a) utilized the SSVS method with a Advances and Applications in Bioinformatics and Chemistry 2008:1 14
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conditional logistic regression likelihood to identify genetic 
loci relevant to a disease using case-parent triads. Oh (2007) 
also coupled the SSVS method with the new Haseman-Elston 
method to perform linkage analysis in rheumatoid arthritis. 
Similarly, Kwon and colleagues (2007) applied an iterative 
SSVS method to ﬁ  nd SNPs that are associated with rheu-
matoid arthritis.
The rest of the paper is organized as follows. First, we 
propose a Bayesian-based methodology to identify the prom-
ising candidate genes that are signiﬁ  cantly more inﬂ  uential 
than the others. Secondly, we evaluate and compare the 
proposed methods using a real dataset in a candidate gene 
study. Finally, we present the discussion and provide the 
conclusion.
Methods
Population
The study population was original to the previous study 
by the CDC Chronic Fatigue Syndrome Research Group. 
More information is available on the website (http://www.
camda.duke.edu/camda06/datasets/index.html). In the pres-
ent study, we only focused on the 42 SNPs as described in 
Table 1. There were 109 subjects, including 55 subjects 
having had experienced chronic fatigue syndrome (CFS) and 
54 nonfatigued controls. In this analysis, we employed the 
71 subjects, including 35 CFS subjects and 36 nonfatigue 
subjects, without any missing SNP values.
Gibbs variable selection
Assume that we observe p SNPs along the genome. Among 
the p SNPs, some may be tightly linked with large effects, 
and others may have only weak effects. Our aim is to identify 
a small number of SNPs that have the greatest discriminating 
power.
We consider binary responses as Yi = 1 indicates that 
the subject has a certain disease and Yi = 0 indicates that the 
subject is a control, for i = 1, ..., n. The observed phenotypic 
value Yj can be described by the linear model as follows 
(Dellaportas et al 2000; Oh et al 2003):
  Yij j j
j
p
=+ +
= ∑ βγ β ε 0
1
X ,  (1)
where Xj is the design matrix, βj the parameter vector related 
to the j th term, and ε ∼ N(0,σ2). In GVS, a set of binary 
indicator variables γj (j = 1, …, p), where γj = 1 or 0 repre-
sents the presence or absence of covariate j in the model, 
respectively.
The prior for (γ, β ) is speciﬁ  ed as f (γ , β ) = f (γ )  f ( β |γ ). 
Furthermore, β can be partitioned into two vectors βγ and β  \γ 
corresponding to those components of β that are included 
(γj = 1) or not included (γj = 0) in the model. Then, the prior 
f (β |γ ) may be partitioned into model prior f (βγ |γ ) and pseu-
doprior f (β  \γ |βγ ,γ ).
The sampling procedure is summarized by the following 
three steps (Dellaportas et al 2000):
1.  We sample the parameters included in the model by the 
posterior
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where y denotes the observed data.
2.  We sample the parameters excluded from the model from 
the pseudoprior
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3.  We sample each variable indicator j from a Bernoulli 
distribution with success probability Oj /(1 + Oj); where 
Oj is given by
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where γ  \  j denotes all terms of γ except γ  j.
For the simplest approach, it is assumed that the prior βj 
depends only on γj and is given by
Table 1 A panel of 42 SNPs by the CDC Chronic Fatigue Syndrome 
Research Group.
Gene SNPs
POMC rs12473543
TH rs4074905,  rs2070762
MAOA  rs1801291, rs979606, rs979605
MAOB  rs3027452, rs2283729, rs1799836
TPH2   rs2171363, rs4760816, rs4760750, rs1386486, rs1487280, 
rs1872824, rs10784941
COMT   rs4646312, rs740603, rs6269, rs4633, rs165722, rs933271, 
rs5993882
NR3C1   rs2918419, rs1866388, rs860458, rs852977, rs6196, 
rs6188, rs258750
SLC6A4  rs2066713, hCV7911132, rs140701
CRHR1   rs110402, rs1396862, rs242940, rs173365, rs242924, 
rs7209436
CRHR2  rs2267710, rs2267714, rs2284217
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The simplified prior (5) results in the following full 
conditional posterior distribution
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A mixture of Normal distribution is used for model 
parameters as follows:
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where μ j, Sj are the mean and variance respectively in the 
corresponding pseudoprior distributions and Σj is the prior 
variance, when the j term is included in the model.
Stochastic search variable selection
and unconditional priors
In summary, we present the similarities and differences 
between the three Bayesian variable selection methods 
including GVS, SSVS, and UP as follows. In the SSVS strat-
egy, unlike GVS and UP, variables corresponding to γj = 0 
are included in the model as follows (George and McCulloch 
1993; Oh et al 2003):
  Yij j
j
p
=+ +
= ∑ ββ ε 0
1
X . (8)
And in the SSVS strategy, βj parameters are constrained to be 
close to zero when γj = 0 (George and McCulloch 1993). In 
this situation, f (y| β ,γ ) is independent of γ. Thus, the ﬁrst term 
on the right hand side of (4) can be omitted as follows:
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In the UP approach, a prior distribution for (γ  ,β ) is speci-
ﬁ  ed with β independent of γ (Kuo and Mallick 1998). Then, 
the second term on the right hand side of (4) is absent as 
follows:
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Two-stage Bayesian variable
selection methodology
In this study, we propose a two-stage selection methodology 
based on GVS. In Stage I, we conduct GVS on all potential 
variables (that is, genetic markers) and calculate the estimated 
posterior probabilities for all potential variables. After rank-
ing the variables according to the posterior probabilities, we 
then select a subset of N variables with top main effects based 
on the estimated posterior probabilities. That is, we identify 
the top N candidate genetic markers in Stage I.
In Stage II, we perform GVS again only on the N variables 
selected in Stage I and rank the selected N variables accord-
ing to the estimated posterior probabilities. Next, we choose 
a small subset of M variables with top main effects based on 
the sorted posterior probabilities. That is, we identify the top 
M candidate genetic markers as a panel of signiﬁ  cant genetic 
markers in Stage II.
Similarly, we can utilize SSVS or UP with the above 
two-stage selection methodology.
OpenBUGS software
The proposed Bayesian methodology can be implemented 
using the OpenBUGS software (Thomas et al 2006). The 
implementation involves the deﬁ  nition with a likelihood of 
the model f (y| β ,γ ) and the speciﬁ  cation of the prior distri-
butions f ( β ,γ )and f (γ )using OpenBUGS (Ntzoufras 2002). 
The posterior probabilities are calculated using OpenBUGS 
and can be monitored using the command “summaryStats” 
in the OpenBUGS environment (Ntzoufras 2002).
When no restrictions on the model space are imposed, 
a common prior for the indicator variables γj is f (γj) = 
Bernoulli(1/2) (Ntzoufras 2002). According to George and 
McCulloch (1993, 1997), the Gibbs sampler should begin 
with all γj = 1, which corresponds to starting with the full 
model. A selection of μ j = 0 and Sj = Σj /k2 with k =10 has 
been proven to be an adequate choice (Ntzoufras 2002). 
The pseudoprior parameters μ j, Sj , and k are only relevant 
to the behavior of the MCMC chain and do not affect the 
posterior distribution (Ntzoufras 2002). Dellaportas and col-
leagues (2000) suggested that the Gibbs sampler is run for 
100,000 iterations for GVS, 500,000 iterations for SSVS, and 
500,000 iterations for UP, respectively, after discarding the 
ﬁ  rst 10,000 iterations for the burn-in period.
Results
We applied the proposed Bayesian strategy to the published 
dataset in CFS as described previously for discovering sig-
niﬁ  cant genes.Advances and Applications in Bioinformatics and Chemistry 2008:1 16
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First, we calculated the estimated marginal posterior 
probabilities based on GVS, SSVS, and UP for all the poten-
tial SNPs by using OpenBUGS. Figure 1 shows the results 
of the estimated marginal posterior probabilities in Stage I. 
Then, we ranked the SNPs according to the estimated mar-
ginal posterior probabilities and selected ten SNPs with top 
main effects. Table 2 summarizes the top ten SNPs based 
on the calculated marginal posterior probabilities in Stage I. 
The results in Figure 1 were based on 100,000 iterations for 
GVS, 500,000 iterations for SSVS, and 500,000 iterations 
for UP, respectively. For all methods, we discarded 10,000 
iterations as a burn-in period. All three methods provided 
similar marginal posterior probabilities in Stage I. As shown 
in Table 2, the top ten SNPs in GVS were the same as the 
ones in UP, although the ranking in GVS was slightly differ-
ent from the one in UP. And there were two different SNPs 
between GVS and SSVS among the top ten SNPs.
Secondly, we calculated the estimated marginal posterior 
probabilities based on GVS, SSVS, and UP again for the 
selected ten SNPs on the ﬁ  rst run. Then, we ranked the SNPs 
according to the estimated marginal posterior probabilities 
and selected ﬁ  ve SNPs with top main effects as a panel of 
signiﬁ  cant SNPs. Table 3 shows the top ﬁ  ve SNPs based on 
Figure 1.
Table 2 In Stage I, the top ten SNPs based on their marginal 
posterior probabilities using the OpenBUGS software for three 
Bayesian variable selection methods including the Gibbs variable 
selection (GVS), the Stochastic Search Variable Selection (SSVS), 
the unconditional priors (UP) approach.
Posterior GVS  SSVS  UP
Ranking
1  hCV7911132 hCV7911132 hCV7911132
2 rs173365  rs1866388  rs173365
3  rs2070762 rs2070762 rs2070762
4 rs6196  rs173365  rs6196
5  rs1866388 rs1801291 rs1866388
6 rs140701  rs6196  rs2267710
7  rs2267710 rs2267710 rs140701
8 rs1801291  rs852977  rs1801291
9  rs852977 rs933271 rs852977
10 rs1396862  rs165722  rs1396862
Table 3 In Stage II, the top ﬁ  ve SNPs based on their marginal 
posterior probabilities using the OpenBUGS software for three 
Bayesian variable selection methods including the Gibbs variable 
selection (GVS), the Stochastic Search Variable Selection (SSVS), 
the unconditional priors (UP) approach.
Posterior Ranking  GVS  SSVS  UP
1 hCV7911132  hCV7911132  hCV7911132
2  rs173365 rs2070762 rs173365
3 rs2070762  rs1866388  rs2070762
4 rs6196  rs173365  rs6196
5 rs1866388  rs6196  rs1866388Advances and Applications in Bioinformatics and Chemistry 2008:1 17
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the calculated marginal posterior probabilities in Stage II. 
The results in Table 3 were based on 100,000 iterations for 
GVS, 500,000 iterations for SSVS, and 500,000 iterations for 
UP, respectively. For all methods, we discarded 10,000 itera-
tions as a burn-in period. All three methods provided similar 
marginal posterior probabilities in Stage II. Furthermore, all 
three methods selected the same top ﬁ  ve SNPs, although the 
ranking in GVS was different from the one in SSVS and was 
the same as the one in UP.
For all three methods, the OpenBUGS programs were run 
on a 2.4 GHz processor. The CPU execution time in Stage 
I was approximately 139 minutes for GVS, 45 minutes for 
SSVS, and 703 minutes for UP, respectively. Furthermore, 
the CPU execution time in Stage II was approximately 9.8 
minutes for GVS, 4 minutes for SSVS, and 60 minutes 
for UP, respectively. Based on the above CPU execution 
time, SSVS seemed to be most efﬁ  cient among these three 
methods.
Discussion
We have developed a Bayesian-based methodology to 
address the problem of identifying genetic markers such as 
SNPs and genes that are more signiﬁ  cant than the others. This 
problem occurs frequently in genomic and epidemiologic 
studies ranging from candidate gene studies to high-density 
genome scans. Our method treats the mapping of genetic 
markers as a problem of model determination and variable 
selection. Variable selection approaches for gene mapping 
include Bayesian methods and frequentist methods (Swartz 
et al 2007b). Several reports compared Bayesian methods 
to frequentist methods and found that the Bayesian meth-
ods may provide fewer false positives (Swartz et al 2007b). 
Because the dimensionality is kept constant across all pos-
sible models, the Bayesian-based methodology can be easily 
implemented via the Gibbs sampler (Dellaportas et al 2000). 
The Bayesian procedure can even be implemented using the 
publicly available software OpenBUGS (Thomas et al 2006) 
and thus can be widely used in genomic studies.
As shown in the MCMC results, we compared three 
Bayesian variable selection strategies including GVS, SSVS, 
and UP. The proposed SSVS method was shown to be more 
efﬁ  cient than two other methods for discovering signiﬁ  cant 
genes under typical situations of a genomics study. These 
three methods are all based on the Gibbs sampler. Com-
pared with the reversible-jump MCMC, the Gibbs sampling 
approach has advantages on simplicity of computation and 
diagnosis of convergence (George and McCulloch 1997). 
Another major advantage is that these methods can be 
easily applied with the Gibbs sampling software such as 
OpenBUGS (Dellaportas et al 2000). The UP approach is 
extremely easy to implement, but may be insufﬁ  ciently ﬂ  ex-
ible for many practical problems (Dellaportas et al 2000). In 
the cases of hundreds of genetic markers, a second iteration 
of SSVS might be considered with a subset of variables based 
on the ﬁ  rst run (George and McCulloch 1993). Accuracy of 
estimating the main effects and the posterior probabilities 
may be improved by using this two-stage strategy (Yi et al 
2003). Similarly, our proposed two-stage Bayesian method 
may have better accuracy by conducting a second run with a 
reduced set of genetic markers based on the ﬁ  rst run. More-
over, Beattie and colleagues (2002) proposed a two-stage 
Bayesian variable selection strategy that incorporates the 
SSVS method with the intrinsic Bayes factor (IBF). In the 
ﬁ  rst stage, the SSVS procedure is employed on all factors. 
Then, in the second stage, the factors identiﬁ  ed in the ﬁ  rst 
stage are used as the input for the IBF analysis. The differ-
ence between our proposed two-stage Bayesian method and 
theirs was that only Bayesian variable selection strategies 
such as GVS, SSVS, and UP were used for both stages in 
our study.
To the best of our knowledge, this is the ﬁ  rst study that 
proposes to use the Bayesian-based approach to provide a 
way to ﬁ  nd a panel of genetic markers that is more signiﬁ  cant 
than the others in CFS. It has been reported that subjects 
with CFS were distinguished by genetic markers that were 
involved in either hypothalanmic-pituitary-adrenal (HPA) 
axis function or neurotransmitter systems, including mono-
amine oxidase A (MAOA), monoamine oxidase B (MAOB), 
nuclear receptor subfamily 3; group C, member 1 glucocor-
ticoid receptor (NR3C1), proopiomelanocortin (POMC) and 
tryptophan hydroxylase 2 (TPH2) genes (Smith et al 2006). 
Moreover, it has been shown that genetic markers, including 
catechol-O-methyltransferase (COMT), NR3C1 and TPH2 
genes, could predict whether a person has CFS (Geortzel et al 
2006). In this study, we identiﬁ  ed signiﬁ  cant SNPs in solute 
carrier family 6 member 4 (SLC6A4), corticotropin releasing 
hormone receptor 1 (CRHR1), tyrosine hydroxylase (TH), 
and NR3C1 genes. An interesting ﬁ  nding was that an associa-
tion of NR3C1 with CFS compared with nonfatigued controls 
appeared to be consistent across several studies. Thus, this 
signiﬁ  cant association strongly suggests that NR3C1 may be 
involved in biological mechanisms with CFS. However, these 
two previous studies (Smith et al 2006; Geortzel et al 2006) 
identiﬁ  ed the TPH2 gene among the reported associations, 
which was not included in this study. The potential reason 
for the discrepancies between the results of this study and Advances and Applications in Bioinformatics and Chemistry 2008:1 18
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those of other studies may be the sample sizes. The studies 
conducted on small populations may have biased a particular 
result. Future research with independent replication in large 
sample sizes is needed to conﬁ  rm the role of the candidate 
genes identiﬁ  ed in this study.
In this study, we focused the context of this paper being 
a candidate gene approach. In future research, we will 
investigate the identiﬁ  ability (Gelfand and Sahu 1999) of 
the proposed method and explore the possibility of extension 
to larger scale problems such as genome-wide association 
studies, where thousands of SNPs for a chromosome scan are 
examined. Moreover, the proposed Bayesian-based method-
ology was employed for modeling genetic markers associated 
with diseases and may be suitable for association studies in 
pharmacogenomics. In the studies of pharmacogenomics, 
genetic markers such as SNPs can be used to understand 
the relationship between genetic inheritance and the body’s 
response to drugs (Lin et al 2006a, 2006b). In future work, 
we aim to investigate the Bayesian-based methodology for 
application in pharmacogenomics.
Furthermore, we focused on the issue of selecting the 
signiﬁ  cant genes without considering epistatic models in this 
study. Epistasis analysis for gene-gene and gene-environment 
interactions have been advocated for deciphering these com-
plex mechanisms, particularly when each involved genetic 
marker only demonstrates a minor marginal effect (Lin et al 
2007a, 2007b). It is important to address gene–gene and 
gene–environment interactions for describing a trait involv-
ing complex disease-related, pharmacokinetic and pharma-
codynamic mechanisms. In future work, we will investigate 
gene–gene and gene–environment interactions based on the 
Bayesian variable selection strategies.
Conclusion
In this study, we propose an alternative Bayesian method for 
assessing signiﬁ  cant genes in genomic studies. Our method is 
based on the Bayesian variable selection methods. Our ﬁ  nd-
ings suggest that our approach may provide a plausible way to 
identify a panel of genetic markers that is more signiﬁ  cant than 
the others. Over the next few years, the results of our studies 
could be utilized to develop molecular diagnostic/prognostic 
tools. However, application of genomics in routine clinical 
practice will become a reality after a prospective clinical trial 
has been conducted to validate genetic markers.
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